Want to know more about partnerships with Novo Nordisk on driving true systemic change that will make a difference for patients worldwide?
We engage in impactful, science-driven, non-competitive Public-Private Partnerships to close gaps in the overall healthcare ecosystem for the benefit of patients and society.
On this page you can find links to the current partnerships that we are part of, and you can find information about, connect with, or even join consortia that propel innovation and change.
Novo Nordisk is an active participant in the EU anchored Innovative Medicines Initiative (IMI) – the world’s largest Public-Private Partnership within life sciences with a total committed budget of more than €5 billion.
Novo Nordisk is a significant IMI contributor with direct involvement in 35+ projects (concluded and ongoing) and will continue this commitment in the IHI framework – the successor to IMI.
“We are very happy to have joined the IMI SOPHIA and work in partnership with Novo Nordisk. This fruitful collaboration offered the possibility for the Medical Informatics Platform, which currently serves multinational consortia to explore decentralised medical data in the field of brain diseases, to extend to the field of obesity.”
- From Prof. Philippe Ryvlin, Head of The Department of Clinical Neurosciences (DNC) at the Lausanne University Hospital (CHUV)